Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 9537632, 5 pages
http://dx.doi.org/10.1155/2016/9537632
Research Article

Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study

1Frauenklinik München West, Schmiedwegerl 2-6, 81242 Munich, Germany
2Institut für Medizinische Forschung, Hufelandstraße 55, 45122 Essen, Germany

Received 28 May 2016; Accepted 26 July 2016

Academic Editor: Vittorio Unfer

Copyright © 2016 Pedro-Antonio Regidor and Adolf Eduard Schindler. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, “Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 24, no. 3, pp. 139–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. L. Croze and C. O. Soulage, “Potential role and therapeutic interests of myo-inositol in metabolic diseases,” Biochimie, vol. 95, no. 10, pp. 1811–1827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-P. Baillargeon, M. J. Iuorno, and J. E. Nestler, “Insulin sensitizers for polycystic ovary syndrome,” Clinical Obstetrics and Gynecology, vol. 46, no. 2, pp. 325–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, and O. Gamba, “Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 114–119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Strugaru, G. Botnariu, L. Agoroaei, I. C. grigoriu, and E. Butnaru, “Metformin induced lactic acidosis—particularities and course,” Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi, vol. 117, no. 4, pp. 1035–1042, 2013. View at Google Scholar
  6. C.-H. Kim, K.-A. Han, H.-J. Oh et al., “Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia,” Journal of Diabetes, vol. 4, no. 4, pp. 395–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. S. Clements Jr. and B. Darnell, “Myo-inositol content of common foods: development of a high-myo-inositol diet,” The American Journal of Clinical Nutrition, vol. 33, no. 9, pp. 1954–1967, 1980. View at Google Scholar · View at Scopus
  8. J. E. F. Reynolds, Martindale: Martindale-the Extra Pharmacopoeia, An Isomer of Glucose that Has Traditionally Been Considered to Be a B Vitamin Although it Has an Uncertain Status as a Vitamin and a Deficiency Syndrome Has not Been Identified in Man, Rittenhouse Book Distributors, Pennsylvania, Pa, USA, 30th edition, 1993.
  9. J.-P. Baillargeon, J. E. Nestler, R. E. Ostlund, T. Apridonidze, and E. Diamanti-Kandarakis, “Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism,” Human Reproduction, vol. 23, no. 6, pp. 1439–1446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. N. M. Hooper, “Glycosyl-phosphatidylinositol anchored membrane enzymes,” Clinica Chimica Acta, vol. 266, no. 1, pp. 3–12, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Carlomagno and V. Unfer, “Inositol safety: clinical evidences,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 8, pp. 931–936, 2011. View at Google Scholar · View at Scopus
  12. M. A. Karimzadeh and M. Javedani, “An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 94, no. 1, pp. 216–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Legro, R. J. Zaino, L. M. Demers et al., “The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome,” American Journal of Obstetrics and Gynecology, vol. 196, no. 4, pp. 402.e1–402.e11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Gerli, E. Papaleo, A. Ferrari, and G. C. Di Renzo, “Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS,” European Review for Medical and Pharmacological Sciences, vol. 11, no. 5, pp. 347–354, 2007. View at Google Scholar · View at Scopus
  15. E. Raffone, P. Rizzo, and V. Benedetto, “Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women,” Gynecological Endocrinology, vol. 26, no. 4, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. D. Genazzani, A. Prati, S. Santagni et al., “Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients,” Gynecological Endocrinology, vol. 28, no. 12, pp. 969–973, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Morgante, R. Orvieto, A. Di Sabatino, M. C. Musacchio, and V. De Leo, “The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen,” Fertility and Sterility, vol. 95, no. 8, pp. 2642–2644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T.-H. Sun, D. B. Heimark, T. Nguygen, J. L. Nadler, and J. Larner, “Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls,” Biochemical and Biophysical Research Communications, vol. 293, no. 3, pp. 1092–1098, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Costantino, G. Minozzi, F. Minozzi, and C. Guaraldi, “Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial,” European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, pp. 105–110, 2009. View at Google Scholar · View at Scopus
  20. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, “Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials,” Gynecological Endocrinology, vol. 28, no. 7, pp. 509–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Kamenov, G. Kolarov, A. Gateva, G. Carlomagno, and A. D. Genazzani, “Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance,” Gynecological Endocrinology, vol. 31, no. 2, pp. 131–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Rizzo, E. Raffone, and V. Benedetto, “Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial,” European Review for Medical and Pharmacological Sciences, vol. 14, no. 6, pp. 555–561, 2010. View at Google Scholar · View at Scopus